The purpose of this observational study is to assess HRQoL in relapsed and/or refractory multiple myeloma (RRMM) participants who have previously received a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody.

Inclusion Criteria:

• Must have sufficient command of the Japanese language to understand the study instructions and requirements

• Must be a resident of Japan

• Must have received prior treatment with:

  1. a proteasome inhibitor,
  2. an immunomodulatory agent, and
  3. an anti-CD38 antibody Subjects must be either 2-4 months, 5-7 months, or 8-11 months post triple class therapy exposure at time of consent

• Subject must be diagnosed with multiple myeloma

Exclusion Criteria:

• Participants enrolled in a clinical trial that includes at least one novel/ experimental agent at the point of questionnaire completion

Other protocol-defined inclusion/exclusion criteria apply.

The target population will consist of approximately 50 participants diagnosed with relapsed/refractory multiple myeloma (RRMM) with triple class therapy exposure identified by physicians.